The document discusses the recent performance and risks in the biotechnology sector, particularly focusing on the Nasdaq Biotech Index (NBI) which experienced a significant drop due to congressional scrutiny over Gilead Sciences' pricing of its hepatitis C drug, Sovaldi. It includes a table of major biotech firms' stock performance and index weight, as well as historical NBI index values and strategies to hedge exposure to the sector.
documents/vol00010-efta01461487-pdf.pdf
{"key_people":["Gilead Sciences"],"document_type":"tabular","key_locations":["US"],"key_organizations":["Nasdaq Biotech Index","Gilead Sciences","ProShares UltraShort Nasdaq Biotech Fund","iSharesNasdaq Biotech ETF"]}